BBT 015

Drug Profile

BBT 015

Alternative Names: BBT-015

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bolder BioTechnology
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols
  • Mechanism of Action Immunostimulants; Neutrophil stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute radiation syndrome; Neutropenia

Most Recent Events

  • 02 Aug 2017 Phase-I clinical trials in Acute radiation syndrome (In volunteers) in USA (SC)
  • 02 Aug 2017 Phase-I clinical trials in Neutropenia (In volunteers) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top